kabutan

Cyfuse Biomedical K.K.(4892) Summary

4892
TSE Growth
Cyfuse Biomedical K.K.
656
JPY
+16
(+2.50%)
Jan 29, 3:03 pm JST
4.28
USD
Jan 29, 1:03 am EST
Result
PTS
outside of trading hours
656.3
Jan 29, 2:57 pm JST
Summary Chart Historical News Financial Result
PER
PBR
2.36
Yield
ー%
Margin Trading Ratio
Stock Price
Jan 29, 2026
Opening Jan 29, 9:00 am
640 JPY 4.18 USD
Previous Close Jan 28
640 JPY 4.19 USD
High Jan 29, 11:29 am
658 JPY 4.30 USD
Low Jan 29, 9:16 am
631 JPY 4.12 USD
Volume
84,300
Trading Value
0.05B JPY 0.36M USD
VWAP
645.98 JPY 4.22 USD
Minimum Trading Value
65,600 JPY 428 USD
Market Cap
6.54B JPY 0.04B USD
Number of Trades
199
Liquidity & Number of Trades
As of Jan 29, 2026
Liquidity
Slightly High
1-Year Average
806
1-Year High Feb 13, 2025
14,682
Margin Trading
Date Short Interest Long Margin Positions Ratio
Jan 23, 2026 0 1,060,800
Jan 16, 2026 0 1,008,000
Jan 9, 2026 0 1,058,500
Dec 26, 2025 0 1,158,900
Dec 19, 2025 0 1,118,100
Company Profile
Cyfuse Biomedical K.K. engages in the development, manufacturing, and sales of regenerative medicine products using bio 3D printers.
Sector
Pharmaceuticals
Cyfuse Biomedical K.K. primarily focuses on the development, manufacturing, and sales of regenerative medicine products using bio 3D printers, while expanding its multifaceted business across three domains: regenerative medicine, drug discovery support, and devices. In the regenerative medicine field, the company develops new regenerative medicine products by creating three-dimensional tissues and organs made solely from cells, advancing multiple pipelines such as peripheral nerve regeneration and bone and cartilage regeneration. In the drug discovery support area, Cyfuse offers contract research services for cell products and develops and sells new 3D cell products like organ models. In the device domain, the company develops and sells bio 3D printers, applies technologies necessary for cell product development, and creates new technologies. Through its proprietary core technology and strategic partnerships, Cyfuse Biomedical K.K. aims to realize innovative regenerative medicine products.